# SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

> **NCT06205316** · PHASE3 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 118 (estimated)

## Conditions studied

- Biochemically Recurrent Prostate Carcinoma
- Oligometastatic Prostate Carcinoma
- Recurrent Prostate Adenocarcinoma
- Stage IIB Prostate Cancer AJCC v8
- Stage IIC Prostate Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Antiandrogen Therapy
- **PROCEDURE:** Biospecimen Collection
- **RADIATION:** Hypofractionated Radiation Therapy
- **PROCEDURE:** Positron Emission Tomography
- **RADIATION:** Stereotactic Body Radiation Therapy
- **OTHER:** Survey Administration
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT06205316
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-22
- **Primary completion:** 2030-01-22
- **Final completion:** 2030-01-22
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06205316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06205316, "SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06205316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*